Stefan Seuferling to take over management of the Gerresheimer Medical Systems Business Unit
Stefan Seuferling, Global Executive Vice President Medical Systems Gerresheimer
Oliver Burgel, Global Executive Vice President Syringe Systems Gerresheimer
Renowned expert succeeds Manfred Baumann
Oliver Burgel assumes global responsibility for newly established Gerresheimer Syringe Systems Business Unit
Düsseldorf/Regensburg/Bünde, Germany, April 28, 2025: Gerresheimer, an innovative system and solution provider and a global partner for the pharma, biotech and cosmetic industries, has arranged the management succession for its Medical Systems Business Unit. Stefan Seuferling will join the Gerresheimer Medical Systems Business Unit as Global Executive Vice President Medical Systems starting in May 2025 and will take over its management in July 2025. He succeeds Manfred Baumann, Global Executive Vice President Sales & Marketing, Administration & TCC Medical Systems, who will retire in late 2025. Stefan Seuferling comes from the medical and pharmaceutical technology company Raumedic, where he was most recently CEO. Previously, the experienced manager held management positions at RTI Surgical and Dräger, among others. At the same time, Gerresheimer has established a new Syringe Systems Business Unit, which will be headed by Oliver Burgel, Global Executive Vice President Syringe Systems. Syringe Systems was previously part of the Medical Systems Business Unit.
"As a proven expert, Stefan Seuferling will continue the successful alignment of our Business Unit and contribute new, forward-looking ideas," explains Manfred Baumann, Global Executive Vice President Sales & Marketing, Administration & TCC Medical Systems. As Managing Director of Gerresheimer Regensburg for many years and Head of the Gerresheimer Business Unit Medical Systems, Manfred Baumann has played a key role in the development of Gerresheimer Medical Systems Business Unit over the past 25 years and has successfully expanded the international scope of the business. Following the onboarding of his successor and the handover of responsibilities, Manfred Baumann will retire in late 2025.
Oliver Burgel takes over management of new Syringe Systems Business Unit To strengthen Gerresheimer's strategic positioning and further accelerate growth, Gerresheimer has created a new global Syringe Systems Business Unit for the syringe business, which was previously part of the Medical Systems Business Unit. The Gerresheimer Center of Excellence for syringes will remain in Buende, Germany, and the new business unit will be headed by Oliver Burgel, Global Executive Vice President Syringe Systems. Oliver Burgel has been with Gerresheimer for more than 12 years and most recently as Senior Executive Vice President Global Operations, Quality and Procurement Medical Systems. Before joining Gerresheimer in 2012, Oliver Burgel held various management positions at MeadWestvaco and Saint-Gobain among others.
About Gerresheimer Gerresheimer is an innovative systems and solutions provider and a global partner for the pharma, biotech and cosmetic industries. The Group offers a comprehensive portfolio of drug containment solutions including closures and accessories, as well as drug delivery systems, medical devices and solutions for the health industry. The product range includes digital solutions for therapy support, medication pumps, syringes, pens, auto-injectors and inhalers as well as vials, cartridges, ampoules, tablet containers, infusion, dropper and syrup bottles and more. Gerresheimer ensures the safe delivery and reliable administration of drugs to the patient. Gerresheimer supports its customers with comprehensive services along the value chain and in addressing the growing demand for enhanced sustainability. With over 40 production sites in 16 countries in Europe, America and Asia, Gerresheimer has a global presence and produces locally for regional markets. Together with Bormioli Pharma, the Group generated revenues of around EUR 2.4bn in 2024 and currently employs around 13,400 people. Gerresheimer AG is listed in the MDAX on the Frankfurt Stock Exchange (ISIN: DE000A0LD6E6).
